News
MyChesCo on MSN2h
ENHERTU plus Pertuzumab Shows Significant Progress in First-Line Treatment for HER2-Positive Breast CancerThe Phase III DESTINY-Breast09 clinical trial has delivered groundbreaking results, demonstrating that ENHERTU® ...
Sinar Daily on MSN12h
New hope for patients with less common breast cancerCommon side effects included nausea, diarrhea and a low white blood cell count, with a less common effect involving lung ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback